Stockscreener 앱 받기
5.29
3.47%
-0.19
시간 외 거래:
5.20
-0.09
-1.70%
전일 마감가:
$5.48
열려 있는:
$5.39
하루 거래량:
4.84M
Relative Volume:
0.63
시가총액:
$411.60M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-1.6741
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
-30.39%
1개월 성능:
-43.36%
6개월 성능:
-62.05%
1년 성능:
-44.02%
1일 변동 폭
$5.01
$5.4851
1주일 범위
$5.00
$6.39
52주 변동 폭
$2.68
$17.00
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
REPL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
5.29 | 427.94M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL - GlobeNewswire Inc.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - PR Newswire
Key resistance and support levels for Replimune Group Inc.Downside Risk Evaluation and Stock Analysis - Newser
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - MarketScreener
Visualizing Replimune Group Inc. stock with heatmapsEntry Timing with Downside Risk Analysis - Newser
Securities Lawsuit Alert: Replimune Group, Inc. (REPL) InvestorsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
Replimune Group Reports Increased Losses Amid Rising R&D Costs - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Stockhouse
Replimune Group, Inc. Sued for Securities Law Violations - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, - GlobeNewswire
Replimune Group (REPL) Reports Wider-than-Expected Quarterly Los - GuruFocus
Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact The Gross Law Firm about pending Class ActionREPL - WV News
Replimune Reports Fiscal First Quarter 2026 Financial Results an - GuruFocus
Biotech Replimune's Q1 net loss widens, cash balance drops - MarketScreener
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance - Stock Titan
Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
Securities Fraud Class Action Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Reminds Investors of September 22, 2025 - ACCESS Newswire
REPL DEADLINE: Replimune Group Investors Should Contact - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - PR Newswire
Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Newsfile
The researchers who designed Replimune's melanoma drug study offer a rare, detailed protest of the FDA's CRL - Endpoints News
Replimune Group, Inc. Stockholders With Large Losses Should Contact Robbins LLP For Information About Leading The REPL Class Action Lawsuit - ACCESS Newswire
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Why Is Replimune Stock Trading Lower On Monday? - Benzinga
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light - MSN
Replimune’s Turmoil: What Comes Next? - StocksToTrade
REPL Stock Drops: A Closer Look - timothysykes.com
Replimune stock plunges after FDA cancer drug rejection details emerge By Investing.com - Investing.com Nigeria
Replimune stock plunges after FDA cancer drug rejection details emerge - Investing.com
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
Replimune stock down after report on drug rejection (REPL) - Seeking Alpha
Advanced analytics toolkit walkthrough for Replimune Group Inc.Chart Confirmation Setup with ROI Signals - Newser
Can trapped investors hope for a rebound in Replimune Group Inc.Free Triple Digit Growth Focused Trade Plan - Newser
Navigating the Fallout: Replimune's FDA Hurdle and the Road to Investor Recovery - AInvest
Replimune Group (REPL.O) Sees Sharp Intraday Move—Here’s Why - AInvest
Bragar Eagel & Squire, P.C. Is Reminds Investors of Class - GlobeNewswire
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):